# Akebia Therapeutics, Inc. (AKBA)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/AKBA/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 102.67M | $ -17.96M | $ -18.76M | $ 53.96M | $ 25.02M |
| 2025 | $ 241.84M | $ -5.47M | $ 69.23M | $ 51.80M | $ 32.61M |
| 2024 | $ 168.36M | $ -72.96M | $ -42.77M | $ 188.73M | $ -49.19M |
| 2023 | $ 210.44M | $ -56.14M | $ -25.28M | $ 48.12M | $ -30.58M |
| 2022 | $ 326.15M | $ -105.70M | $ -81.85M | $ 99.78M | $ 5.23M |
| 2021 | $ 251.58M | $ -335.23M | $ -300.76M | $ 189.13M | $ 74.01M |
| 2020 | $ 376.20M | $ -488.50M | $ -141.15M | $ 126.29M | $ 247.62M |
| 2019 | $ 432.40M | $ -360.97M | $ -340.88M | $ 108.32M | $ 394.76M |
| 2018 | $ 274.36M | $ -227.03M | $ -130.88M | $ 15.00M | $ 635.93M |
| 2017 | $ 239.77M | $ -103.61M | $ -77.84M | $ 0 | $ 119.33M |
| 2016 | $ 2.11M | $ -186.76M | $ 76.01M | $ 0 | $ 68.12M |
| 2015 | $ 0 | $ -85.25M | $ -74.16M | $ 0 | $ 131.00M |
| 2014 | $ 0 | $ -52.33M | $ -39.16M | $ 0 | $ 104.08M |
| 2013 | $ 0 | $ -18.73M | $ -16.14M | $ 11.9K | $ 30.76M |
| 2012 | $ 0 | $ -4.70M | $ -2.85M | $ 0 | $ 1.47M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 2.16 |
| Liabilities / Eq | 12.98 |
| Current Ratio | 1.43 |

## Other views

- [Metrics](https://sponda.capital/en/AKBA.md)
- [Charts](https://sponda.capital/en/AKBA/charts.md)
- [Compare](https://sponda.capital/en/AKBA/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-27.